1. Biological therapy and the immune system in patients with chronic myeloid leukemia

   • Peter Rohon

   Review Article 04 June 2012 Pages: 1 - 9

   

2. Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis

   • Kentaro Minagawa
   • Motohiro Yamamori
   • Toshimitsu Matsui

   Review Article 17 May 2012 Pages: 10 - 25

   

3. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care

   • Roberto Stasi
   • Magaral Murali
   • Mark D. Danese

   Original Article 05 May 2012 Pages: 26 - 33

   

4. Diagnosis of acquired bone marrow failure syndrome during childhood using the 2008 World Health Organization classification system

   • Wenyu Yang
   • Peihong Zhang
   • Xiaofan Zhu

   Original Article 06 May 2012 Pages: 34 - 38

5. Molecular analysis of afibrinogenemic mutations caused by a homozygous FGA1238 bp deletion, and a compound heterozygous FGA1238 bp deletion and novel FGA c.54+3A>C substitution

   • Yuka Takezawa
   • Fumiko Terasawa
   • Nobuo Okumura

   Original Article 26 May 2012 Pages: 39 - 46

   

6. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation

   • Dongho Kim
   • Hyun Gyung Goh
   • Dong-Wook Kim

   Original Article 19 May 2012 Pages: 47 - 57

   

7. High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score

   • Vít Procházka
   • Edgar Faber
   • Tomáš Papajík

   Original Article 26 May 2012 Pages: 58 - 64

   

8. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia

   • Hui Yang
   • Hui Liang
   • Li-yuan Ma

   Original Article 07 June 2012 Pages: 65 - 73

   

9. Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low–intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508

   • Yoshitoyo Kagami
   • Kuniaki Itoh
   • The members of the Lymphoma Study Group of the Japan Clinical Oncology Group

   Original Article 03 June 2012 Pages: 74 - 83

   

10. Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study

    • Atsushi Wakita
    • Shigeki Ohtake
    • Ryuzo Ohno

    Original Article 26 May 2012 Pages: 84 - 93

    

11. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients

    • Katsuto Takenaka
    • Koji Nagafuji
    • Koichi Akashi

    Original Article 01 May 2012 Pages: 94 - 100

    

12. Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients

    • Kazuhiro Ikegame
    • Katsuji Kaida
    • Hiroyasu Ogawa

    Original Article 25 May 2012 Pages: 101 - 108

13. Characteristics and influencing factors of CD19+ B cell reconstitution in patients following haploidentical/mismatched hematopoietic stem cell transplantation

    • Min Xie
    • Hai-Xia Fu
    • Xiao-Jun Huang

    Original Article 07 June 2012 Pages: 109 - 121

    

14. Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange

    • Parameswaran Narayanan
    • Aparna Jayaraman
    • Sreejith Parameswaran

    Case Report 03 May 2012 Pages: 122 - 124

    

15. Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation

    • Victor H. Jimenez-Zepeda
    • Rajkumar Vajpeyi
    • Suzanne Trudel

    Case Report 10 May 2012 Pages: 125 - 131

    

16. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia

    • Dariusz Zakrzewski
    • Ilona Seferynska
    • Tomasz Hryniewiecki

    Case Report 26 May 2012 Pages: 132 - 135

    

17. Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to l-asparaginase

    • Hiroyoshi Takahashi
    • Katsuyoshi Koh
    • Ryoji Hanada

    Case Report 29 May 2012 Pages: 136 - 140

    

18. Splenic infarction, warm autoimmune hemolytic anemia and antiphospholipid antibodies associated with systemic lupus erythematosus

    • Irfan Yavasoglu
    • Gurhan Kadikoylu
    • Zahit Bolaman

    Letter to the Editor 24 May 2012 Pages: 141 - 141

19. Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy

    • Fabio Stagno
    • Paolo Vigneri
    • Francesco Di Raimondo

    Letter to the Editor 26 May 2012 Pages: 142 - 143

20. On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS)

    • Guillermo J. Ruiz-Argüelles
    • Guillermo J. Ruiz-Delgado

    Letter to the Editor 03 June 2012 Pages: 144 - 145

21. Efficacy of pleural biopsy for diagnosis of pleural effusion due to chronic GVHD after hematopoietic stem cell transplantation

    • Masashi Miyauchi
    • Akihide Yoshimi
    • Mineo Kurokawa

    Letter to the Editor 09 June 2012 Pages: 146 - 148